GlaxoSmithKline Appoints Directors to Board of New Consumer-Health Company Haleon
March 15 2022 - 6:47AM
Dow Jones News
By Cecilia Butini
GlaxoSmithKline PLC said Tuesday that it has appointed six
directors to the board of Haleon, the new company set to be formed
through the demerger of Glaxo's consumer healthcare unit.
The British pharma giant said the appointments include two Glaxo
nonexecutive directors and three new external members. Haleon's
chief financial officer designate Tobias Hestler is expected to
become executive director together with Chief Executive Officer
Designate Brian McNamara, Glaxo said.
Mr. Hestler is exepected to be appointed as director prior to
the company's demerger, which is expected in July 2022, while all
the other appointments are to become effective starting from the
demerger, Glaxo said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 15, 2022 06:32 ET (10:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
